Alimera Announces Scientific Data Highlighting ILUVIEN To Be Presented At The American Academy Of Ophthalmology

Author: Benzinga Newsdesk | October 31, 2023 08:08am

Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg taken from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN for patients with diabetic macular edema, will be featured in three posters and a presentation on behalf of the PALADIN Investigators, during the American Academy of Ophthalmology's 127th Annual Meeting being held in San Francisco from November 3-6, 2023.

Presentation:

Pauline Merrill, MD "0.19 mg Fluocinolone Acetonide Implant Improves Vision and Treatment Burden in Patients with DME: The PALADIN Study"

(Sunday November 5, 4:45 p.m. PST)

Posters:

David Chin-Yee, MD "Outcomes in Eyes Requiring IOP Lowering Surgery After Treatment with the 0.19 Fluocinolone Acetonide Implant for DME: The PALADIN Study"

(Poster Session PO562)

Daniel Kiernan, MD "0.19 mg Fluocinolone Acetonide Implant Leads to Superior DME Treatment Outcomes in Eyes with Better Baseline Visual Acuity (≥20/40)"

(Poster Session PO522)

Mathew MacCumber, MD, PhD Control of Retinal Thickness Variability Improves Vision Following the 0.19mg Fluocinolone Acetonide Implant in Patients with DME"

(Poster Session PO518)

Posted In: ALIM